Attributing the strong show in Q3FY17 to robust performance in biologics, Biocon Chairperson and MD Kiran Mazumdar-Shaw told CNBC-TV18 that Biocon is well poised to be front-runner in biosimilars. The acceptance of biosimilar Trastuzumab by the USFDA is a huge milestone for Mylan and Biocon, she said.
first published: Jan 25, 2017 11:02 am
A collection of the most-viewed Moneycontrol videos.
JD Vance May Visit Pakistan For Second Round Of Peace Talks With Iran: Reports
Trump Claims Iran N-Sites ‘Obliterated’: ‘Digging Nuclear Dust Won’t Be Easy’
PAN Misuse Alert | How to Check If Someone Opened Bank Accounts in Your Name
Oil prices range bound| Trump renews threat of ‘bombing’ Iran | Nifty set for a cautious start
